UPMC has joined the American Heart Association and Dutch health technology company Royal Philips in a new $30 million venture capital fund.
With investments of $10 million from each partner, Cardeation Capital will invest in heart-related diagnostics, treatments and devices that address cardiovascular disease.
It is the first investment of its kind for the AHA, but the latest for Pittsburgh health system UPMC in a long quest for new sources of revenue at a time when government payment for the institution’s core medical services is falling.
“There are a lot of good ideas out there that we can accelerate with innovations,” said Joon Sup Lee, co-director of the UPMC Heart and Vascular Institute. “There’s nothing more important than your heart.”

Cardeation Capital will be managed by Mill Valley, Calif.-based Aphelion Capital, which specializes in life science investments. The fund is unrestricted in where it looks for places to invest.
For years, UPMC has invested in new technologies to spin out startup companies and generate new revenue, but the effort was ramped up and rebranded in 2015 with the creation of UPMC Enterprises.
The commercialization arm of the hospital and health insurance giant focuses on speeding research breakthroughs to the patient’s bedside through innovation and on streamlining the lowering the cost of medical care through new technologies.
Meanwhile, Philips employs more than 1,700 people in the Pittsburgh area after acquiring Murrysville-based Respironics in 2008.
Last year, the company leased 14,000-square-feet of space in Oakland’s new Schenley Place, where it moved more than 100 of its employees to be closer to the city’s universities, medical centers and research partners.
Philips also collaborates with the University of Pittsburgh in talent development, addressing health care needs and commercializing technology.
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.